GET DAILY SIGNALSICON plc (ICLR) Climbs +24% Over 30 Days After Earnings Beat
Key Takeaways
- ICLR climbed roughly 24% over the past 30 days, rising from about $170 to near $211, powered largely by a better-than-expected third-quarter earnings report.
- The stock surged around 17% in a single session on October 28 after ICON posted adjusted earnings that topped analyst expectations.
- ICON reported Q3 adjusted earnings per share of $2.66 on revenue of about $2.02 billion, with revenue essentially flat year over year.
- A year-to-date book-to-bill ratio of roughly 1.49x and several post-earnings analyst price-target increases reinforced the rally.
- Over the last three months, ICLR is up roughly 28%, extending its recovery from an early-2026, restatement-driven selloff.
- Readers can explore ICON's Price Targets, Earnings, and Forecast on dedicated pages for additional detail.
ICON plc (ICLR) at a Glance: Business and Competitive Landscape
ICON plc is a Dublin, Ireland-headquartered healthcare intelligence and clinical research organization (CRO). The company provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government and public health organizations, helping sponsors bring new drugs and devices to market more efficiently. Its offerings span clinical trial management, patient recruitment, data analytics, regulatory consulting, and central laboratory services.
As one of the world's largest CROs, ICON competes with peers such as IQVIA Holdings (IQV) and Labcorp (LH) on global scale, therapeutic breadth, and integrated data and technology capabilities. Investors follow ICLR closely because its backlog and book-to-bill metrics are leading indicators of biopharma R&D spending and future revenue growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ICLR Stock Performance: Recent 30-Day and Quarterly Moves
Over the past 30 days, ICLR rose from a closing price of about $169.99 on September 30 to $211.36 on October 30, a gain of roughly 24%. The move was concentrated in the final trading sessions of the period, when the stock jumped sharply following its third-quarter earnings release.
The broader three-month trend has been similarly positive. ICLR ended late July near $165.53 and finished October around $211.36, an increase of roughly 28%. The path, however, was uneven: shares slid from about $180 in late July to a low near $157 in early August, then traded in a wide range through September and early October before the earnings-driven breakout. From what I see, the recovery momentum looks solid but still needs confirmation from upcoming results.
Key Catalysts Behind the Recent ICLR Rally
The dominant catalyst was ICON's third-quarter results, released after the market closed on October 27. The company reported adjusted earnings per share of $2.66, modestly above consensus, on revenue of approximately $2.02 billion that was essentially flat compared with the prior-year period. The earnings beat triggered a roughly 17% single-day advance on October 28.
Investor enthusiasm was supported by durable demand signals. ICON reported a year-to-date book-to-bill ratio of about 1.49x, indicating it continues to win new business faster than it recognizes revenue, with management signaling improved visibility into 2027. A series of analyst actions followed the report, including a price-target increase to $226 by RBC Capital, a $240 target from Evercore ISI, and a $228 target from Mizuho. Capital-allocation news also underpinned sentiment, as ICON repurchased roughly $400 million of stock at an average price near $170 during the quarter, and in August it completed a $2.15 billion investment-grade bond issuance used to refinance outstanding debt.
Quarterly Recovery Context and Broader Narrative
The quarterly advance reflects a broader recovery narrative. ICON's shares suffered a roughly 40% single-session decline on February 12, 2026, after the company disclosed an audit committee investigation into its revenue recognition. The audit committee later concluded its work, and ICON confirmed it would restate results for 2023, 2024, and the first nine months of 2025 while stating there was no impact on customers, operations, or cash flow.
Since then, the stock has rebuilt value as investors refocused on improving CRO demand and ICON's strong bookings. In October, BofA upgraded the stock to Neutral from Underperform, citing a healthier demand backdrop and sustained direct-fee bookings. The third-quarter earnings beat and multiple price-target increases extended that recovery into late October. I'm watching this closely as the restatement overhang appears to be fading.
Forward Outlook: What Could Shape ICLR Next
Going forward, investors will be watching whether ICON's strong book-to-bill ratio converts into revenue growth and margin recovery. The company's year-to-date adjusted EBITDA margin of roughly 16% remains below prior-year levels, so sustained margin stabilization will be a key focus. Upcoming quarterly results and management guidance will indicate whether the bookings strength is translating into financial performance.
Broader industry factors also matter, including pharmaceutical and biotech R&D spending trends, demand across the CRO sector, competitive positioning against large peers, and any further developments related to the completed restatement. Valuation remains a point of debate as the stock re-rates, and investors will likely monitor analyst estimate revisions alongside the company's execution on its backlog.
Exploring AI-Driven Trading Strategies
I’ve found Tickeron’s Trending AI Robots to be a useful resource when evaluating how automated strategies are positioning around stocks like ICLR. The page highlights top-performing bots from a larger library, showing varied approaches and timeframes that can help put current price action into context. It offers a practical way to review data-driven signals without replacing your own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICLR in upward trend: 10-day moving average moved above 50-day moving average on October 20, 2026
The 10-day moving average for ICLR crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICLR as a result. In 63 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for ICLR just turned positive on October 15, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +17.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 202 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 134 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ICLR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ICLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.739) is normal, around the industry mean (65.853). ICLR's P/E Ratio (315.463) is considerably higher than the industry average of (2.707). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of clinical research and development services
Industry MedicalSpecialties
Advertisement